IL17A and non-small cell lung carcinoma: These findings are essentially in agreement with several earlier experimental studies in murine models of experimental colon cancer and NSCLC, in which neutrophilic inflammation resulting from tumor expression of the neutrophil-recruiting cytokine IL-17A was associated with disease progression and decreased responsiveness to PD-1-targeted immunotherapy [39,40].